Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease


You May Also Like

FIT Biotech Oy: FIT Biotech concludes the exploration of secondary listing to First North Sweden -not relevant at the moment

FIT Biotech Oy                                                             Company release 16.8.2018 at 4:30 PM EET FIT Biotech concludes the ...

Galena Biopharma Reports Second Quarter 2017 Financial Results

SAN RAMON, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a ...